Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53


IDH1 R132H predicts sensitivity to Bcl-xL inhibition-mediated programmed cell death.

Karpel-Massler G, Ishida CT, Siegelin MD.

Oncotarget. 2017 Dec 18;9(1):1-2. doi: 10.18632/oncotarget.23399. eCollection 2018 Jan 2. No abstract available.


Cell death-based treatment of childhood cancer.

Westhoff MA, Marschall N, Grunert M, Karpel-Massler G, Burdach S, Debatin KM.

Cell Death Dis. 2018 Jan 25;9(2):116. doi: 10.1038/s41419-017-0062-z. Review.


The effects of PI3K-mediated signalling on glioblastoma cell behaviour.

Langhans J, Schneele L, Trenkler N, von Bandemer H, Nonnenmacher L, Karpel-Massler G, Siegelin MD, Zhou S, Halatsch ME, Debatin KM, Westhoff MA.

Oncogenesis. 2017 Nov 29;6(11):398. doi: 10.1038/s41389-017-0004-8.


Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL.

Karpel-Massler G, Ishida CT, Bianchetti E, Zhang Y, Shu C, Tsujiuchi T, Banu MA, Garcia F, Roth KA, Bruce JN, Canoll P, Siegelin MD.

Nat Commun. 2017 Oct 20;8(1):1067. doi: 10.1038/s41467-017-00984-9.


Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen.

Kast RE, Skuli N, Karpel-Massler G, Frosina G, Ryken T, Halatsch ME.

Oncotarget. 2017 Jun 1;8(37):60727-60749. doi: 10.18632/oncotarget.18337. eCollection 2017 Sep 22.


Anti-glioma Activity of Dapsone and Its Enhancement by Synthetic Chemical Modification.

Karpel-Massler G, Kast RE, Siegelin MD, Dwucet A, Schneider E, Westhoff MA, Wirtz CR, Chen XY, Halatsch ME, Bolm C.

Neurochem Res. 2017 Dec;42(12):3382-3389. doi: 10.1007/s11064-017-2378-6. Epub 2017 Aug 29.


The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy.

Kast RE, Skuli N, Cos S, Karpel-Massler G, Shiozawa Y, Goshen R, Halatsch ME.

Breast Cancer (Dove Med Press). 2017 Jul 11;9:495-514. doi: 10.2147/BCTT.S139963. eCollection 2017.


Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma.

Karpel-Massler G, Ishida CT, Zhang Y, Halatsch ME, Westhoff MA, Siegelin MD.

Expert Opin Drug Discov. 2017 Oct;12(10):1031-1040. doi: 10.1080/17460441.2017.1356286. Epub 2017 Jul 20. Review.


BET-inhibitors as sensitizers for BH3-mimetics.

Ishida CT, Karpel-Massler G, Siegelin MD.

Aging (Albany NY). 2017 Jun 26;9(6):1475-1476. doi: 10.18632/aging.101259. No abstract available.


Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.

Karpel-Massler G, Ishida CT, Bianchetti E, Shu C, Perez-Lorenzo R, Horst B, Banu M, Roth KA, Bruce JN, Canoll P, Altieri DC, Siegelin MD.

Cancer Res. 2017 Jul 1;77(13):3513-3526. doi: 10.1158/0008-5472.CAN-16-3424. Epub 2017 May 18.


Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin.

Kast RE, Hill QA, Wion D, Mellstedt H, Focosi D, Karpel-Massler G, Heiland T, Halatsch ME.

Tumour Biol. 2017 May;39(5):1010428317699797. doi: 10.1177/1010428317699797. Review.


BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.

Ishida CT, Bianchetti E, Shu C, Halatsch ME, Westhoff MA, Karpel-Massler G, Siegelin MD.

Oncotarget. 2017 May 2;8(18):29558-29573. doi: 10.18632/oncotarget.16365.


Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma.

Ishida CT, Shu C, Halatsch ME, Westhoff MA, Altieri DC, Karpel-Massler G, Siegelin MD.

Oncotarget. 2017 Jun 6;8(23):37140-37153. doi: 10.18632/oncotarget.16202.


Simultaneous Interference with HER1/EGFR and RAC1 Signaling Drives Cytostasis and Suppression of Survivin in Human Glioma Cells in Vitro.

Karpel-Massler G, Westhoff MA, Kast RE, Dwucet A, Karpel-Massler S, Nonnenmacher L, Siegelin MD, Wirtz CR, Debatin KM, Halatsch ME.

Neurochem Res. 2017 May;42(5):1543-1554. doi: 10.1007/s11064-017-2213-0. Epub 2017 Mar 7.


Cell Death Induction in Cancer Therapy - Past, Present, and Future.

Nonnenmacher L, Hasslacher S, Zimmermann J, Karpel-Massler G, La Ferla-Brühl K, Barry SE, Burster T, Siegelin MD, Brühl O, Halatsch ME, Debatin KM, Westhoff MA.

Crit Rev Oncog. 2016;21(3-4):253-267. Review.


Bcl-xL inhibition - a novel strategy for glioma therapy.

Karpel-Massler G, Siegelin MD.

Aging (Albany NY). 2016 Sep 28;8(9):1830-1831. doi: 10.18632/aging.101074. No abstract available.


Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ Regimen.

Salacz ME, Kast RE, Saki N, Brüning A, Karpel-Massler G, Halatsch ME.

Onco Targets Ther. 2016 Apr 27;9:2535-45. doi: 10.2147/OTT.S100407. eCollection 2016. Review.


Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo.

Karpel-Massler G, Ramani D, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD.

Oncotarget. 2016 Jun 7;7(23):33512-28. doi: 10.18632/oncotarget.9257.


A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers.

Karpel-Massler G, Horst BA, Shu C, Chau L, Tsujiuchi T, Bruce JN, Canoll P, Greene LA, Angelastro JM, Siegelin MD.

Clin Cancer Res. 2016 Sep 15;22(18):4698-711. doi: 10.1158/1078-0432.CCR-15-2827. Epub 2016 Apr 28.


Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo.

Karpel-Massler G, Banu MA, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD.

Oncotarget. 2016 Mar 15;7(11):12791-805. doi: 10.18632/oncotarget.7302.


Regression/eradication of gliomas in mice by a systemically-deliverable ATF5 dominant-negative peptide.

Cates CC, Arias AD, Nakayama Wong LS, Lamé MW, Sidorov M, Cayanan G, Rowland DJ, Fung J, Karpel-Massler G, Siegelin MD, Greene LA, Angelastro JM.

Oncotarget. 2016 Mar 15;7(11):12718-30. doi: 10.18632/oncotarget.7212.


A paired comparison between glioblastoma "stem cells" and differentiated cells.

Schneider M, Ströbele S, Nonnenmacher L, Siegelin MD, Tepper M, Stroh S, Hasslacher S, Enzenmüller S, Strauss G, Baumann B, Karpel-Massler G, Westhoff MA, Debatin KM, Halatsch ME.

Int J Cancer. 2016 Apr 1;138(7):1709-18. doi: 10.1002/ijc.29908. Epub 2015 Nov 17.


TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.

Karpel-Massler G, Bâ M, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD.

Oncotarget. 2015 Nov 3;6(34):36456-71. doi: 10.18632/oncotarget.5505.


A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.

Ströbele S, Schneider M, Schneele L, Siegelin MD, Nonnenmacher L, Zhou S, Karpel-Massler G, Westhoff MA, Halatsch ME, Debatin KM.

PLoS One. 2015 Jun 29;10(6):e0131670. doi: 10.1371/journal.pone.0131670. eCollection 2015. Erratum in: PLoS One. 2015;10(7):e0134770. Karpel-Massle, Georg [corrected to Karpel-Massler, Georg].


Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo.

Karpel-Massler G, Shu C, Chau L, Banu M, Halatsch ME, Westhoff MA, Ramirez Y, Ross AH, Bruce JN, Canoll P, Siegelin MD.

Oncotarget. 2015 Jun 10;6(16):14507-21.


First Report of Recurrent Intramuscular Lipoma after Decompression Surgery of the Lumbar Spine.

Klessinger S, Freund W, Karpel-Massler G, Wirtz C, Thal D, Halatsch ME.

J Neurol Surg A Cent Eur Neurosurg. 2016 Jan;77(1):68-72. doi: 10.1055/s-0034-1376193. Epub 2015 Apr 27.


PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.

Karpel-Massler G, Pareja F, Aimé P, Shu C, Chau L, Westhoff MA, Halatsch ME, Crary JF, Canoll P, Siegelin MD.

PLoS One. 2014 Dec 22;9(12):e114583. doi: 10.1371/journal.pone.0114583. eCollection 2014.


Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.

Karpel-Massler G, Kast RE, Westhoff MA, Dwucet A, Welscher N, Nonnenmacher L, Hlavac M, Siegelin MD, Wirtz CR, Debatin KM, Halatsch ME.

J Neurooncol. 2015 Mar;122(1):21-33. doi: 10.1007/s11060-014-1688-7. Epub 2014 Dec 19.


RIST: a potent new combination therapy for glioblastoma.

Nonnenmacher L, Westhoff MA, Fulda S, Karpel-Massler G, Halatsch ME, Engelke J, Simmet T, Corbacioglu S, Debatin KM.

Int J Cancer. 2015 Feb 15;136(4):E173-87. doi: 10.1002/ijc.29138. Epub 2014 Sep 1.


Molecular, histopathological, and genomic variants of glioblastoma.

Karsy M, Huang T, Kleinman G, Karpel-Massler G.

Front Biosci (Landmark Ed). 2014 Jun 1;19:1065-87. Review.


Response to transforaminal injection of steroids and correlation to mri findings in patients with cervical radicular pain or radiculopathy due to disc herniation or spondylosis.

Klessinger S, Freund W, Karpel-Massler G, Halatsch ME.

Pain Med. 2014 Jun;15(6):929-37. doi: 10.1111/pme.12415. Epub 2014 Mar 10.


Killing me softly--future challenges in apoptosis research.

Westhoff MA, Brühl O, Nonnenmacher L, Karpel-Massler G, Debatin KM.

Int J Mol Sci. 2014 Mar 3;15(3):3746-67. doi: 10.3390/ijms15033746. Review.


Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines.

Karpel-Massler G, Westhoff MA, Kast RE, Dwucet A, Nonnenmacher L, Wirtz CR, Debatin KM, Halatsch ME.

Anticancer Agents Med Chem. 2014 Feb;14(2):313-8.


A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy.

Westhoff MA, Karpel-Massler G, Brühl O, Enzenmüller S, La Ferla-Brühl K, Siegelin MD, Nonnenmacher L, Debatin KM.

Mol Cell Ther. 2014 Oct 27;2:32. doi: 10.1186/2052-8426-2-32. eCollection 2014. Review.


Phosphoinositide 3-kinases upregulate system xc(-) via eukaryotic initiation factor 2α and activating transcription factor 4 - A pathway active in glioblastomas and epilepsy.

Lewerenz J, Baxter P, Kassubek R, Albrecht P, Van Liefferinge J, Westhoff MA, Halatsch ME, Karpel-Massler G, Meakin PJ, Hayes JD, Aronica E, Smolders I, Ludolph AC, Methner A, Conrad M, Massie A, Hardingham GE, Maher P.

Antioxid Redox Signal. 2014 Jun 20;20(18):2907-22. doi: 10.1089/ars.2013.5455. Epub 2014 Feb 6.


Inhibition of NF-κB signaling ablates the invasive phenotype of glioblastoma.

Westhoff MA, Zhou S, Nonnenmacher L, Karpel-Massler G, Jennewein C, Schneider M, Halatsch ME, Carragher NO, Baumann B, Krause A, Simmet T, Bachem MG, Wirtz CR, Debatin KM.

Mol Cancer Res. 2013 Dec;11(12):1611-23. doi: 10.1158/1541-7786.MCR-13-0435-T. Epub 2013 Oct 21.


Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells.

Karpel-Massler G, Westhoff MA, Zhou S, Nonnenmacher L, Dwucet A, Kast RE, Bachem MG, Wirtz CR, Debatin KM, Halatsch ME.

Mol Cancer Ther. 2013 Sep;12(9):1783-95. doi: 10.1158/1535-7163.MCT-13-0052. Epub 2013 Jul 5.


A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.

Kast RE, Boockvar JA, Brüning A, Cappello F, Chang WW, Cvek B, Dou QP, Duenas-Gonzalez A, Efferth T, Focosi D, Ghaffari SH, Karpel-Massler G, Ketola K, Khoshnevisan A, Keizman D, Magné N, Marosi C, McDonald K, Muñoz M, Paranjpe A, Pourgholami MH, Sardi I, Sella A, Srivenugopal KS, Tuccori M, Wang W, Wirtz CR, Halatsch ME.

Oncotarget. 2013 Apr;4(4):502-30. Review.


GDC-0941 enhances the lysosomal compartment via TFEB and primes glioblastoma cells to lysosomal membrane permeabilization and cell death.

Enzenmüller S, Gonzalez P, Karpel-Massler G, Debatin KM, Fulda S.

Cancer Lett. 2013 Feb 1;329(1):27-36. doi: 10.1016/j.canlet.2012.09.007. Epub 2012 Sep 18.


Why dapsone stops seizures and may stop neutrophils' delivery of VEGF to glioblastoma.

Kast RE, Lefranc F, Karpel-Massler G, Halatsch ME.

Br J Neurosurg. 2012 Dec;26(6):813-7. doi: 10.3109/02688697.2012.674577. Epub 2012 May 2. Review.


Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma.

Pala A, Karpel-Massler G, Kast RE, Wirtz CR, Halatsch ME.

Cancers (Basel). 2012 May 8;4(2):523-30. doi: 10.3390/cancers4020523.


Erlotinib in glioblastoma: lost in translation?

Karpel-Massler G, Westhoff MA, Kast RE, Wirtz CR, Halatsch ME.

Anticancer Agents Med Chem. 2011 Oct;11(8):748-55. Review.


The rationale of targeting neutrophils with dapsone during glioblastoma treatment.

Kast RE, Scheuerle A, Wirtz CR, Karpel-Massler G, Halatsch ME.

Anticancer Agents Med Chem. 2011 Oct;11(8):756-61. Review.


Drug combinations enhancing the antineoplastic effects of erlotinib in high-grade glioma.

Karpel-Massler G, Wirtz CR, Halatsch ME.

Recent Pat Anticancer Drug Discov. 2011 Sep;6(3):384-94. doi: 10.2174/157489211796957748. Review.


Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.

Unterkircher T, Cristofanon S, Vellanki SH, Nonnenmacher L, Karpel-Massler G, Wirtz CR, Debatin KM, Fulda S.

Clin Cancer Res. 2011 Jun 15;17(12):4019-30. doi: 10.1158/1078-0432.CCR-11-0075. Epub 2011 Apr 27.


Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?

Kast RE, Karpel-Massler G, Halatsch ME.

Br J Pharmacol. 2011 Nov;164(5):1393-6. doi: 10.1111/j.1476-5381.2011.01320.x.


Ribozyme-mediated inhibition of 801-bp deletion-mutant epidermal growth factor receptor mRNA expression in glioblastoma multiforme.

Karpel-Massler G, Wirtz CR, Halatsch ME.

Molecules. 2010 Jun 30;15(7):4670-8. doi: 10.3390/molecules15074670. Review.


Autoregulation and brain metabolism in the perihematomal region of spontaneous intracerebral hemorrhage: an observational pilot study.

Diedler J, Karpel-Massler G, Sykora M, Poli S, Sakowitz OW, Veltkamp R, Steiner T.

J Neurol Sci. 2010 Aug 15;295(1-2):16-22. doi: 10.1016/j.jns.2010.05.027. Epub 2010 Jun 16.


Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?

Karpel-Massler G, Schmidt U, Unterberg A, Halatsch ME.

Mol Cancer Res. 2009 Jul;7(7):1000-12. doi: 10.1158/1541-7786.MCR-08-0479. Epub 2009 Jul 7. Review.

Supplemental Content

Loading ...
Support Center